

Federal Employee Program. (gemtuzumab ozogamicin)

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

- 1. Relapsed or refractory CD33-positive acute myeloid leukemia (AML)
 - a. 2 years of age or older
- 2. Newly-diagnosed CD33-positive acute myeloid leukemia (AML)
 - a. 1 month of age or older
 - b. Age 1 month 17 years of age **only**: used in combination with standard chemotherapy

AND ALL of the following:

- 1. CD33-positive AML as detected by FDA-approved test
- Prescriber agrees to monitor ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose of Mylotarg

Prior - Approval Limits

Duration 12 months

Prior – Approval Renewal Requirements

Age 1 month of age or older

Diagnosis

Patient must have the following:

CD33-positive acute myeloid leukemia (AML)

AND ALL of the following:

- a. NO disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose of Mylotarg

Prior - Approval Renewal Limits

Same as above